There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update / M. Reig, A. Forner, J. Rimola, J. Ferrer-Fàbrega, M. Burrel, Á. Garcia-Criado, R.K. Kelley, P.R. Galle, V. Mazzaferro, R. Salem, B. Sangro, A.G. Singal, A. Vogel, J. Fuster, C. Ayuso, J. Bruix. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 76:3(2022), pp. 681-693. [10.1016/j.jhep.2021.11.018]

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

V. Mazzaferro;
2022

Abstract

There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.
AFP; ALBI score; BCLC; HCC; TARE; ablation; liver transplantation TACE; surgery; survival; systemic treatment; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Severity of Illness Index; Prognosis
Settore MED/06 - Oncologia Medica
Settore MED/12 - Gastroenterologia
2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
PIIS0168827821022236.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/915209
Citazioni
  • ???jsp.display-item.citation.pmc??? 1196
  • Scopus 1932
  • ???jsp.display-item.citation.isi??? 1852
social impact